Abstract:
There were 64 male gender patients from December 2020 until July 202l in Multidisciplinary clinic of Tashkent Medical Academy with acute iliofemoral venous
thrombosis, which were divided into 2 groups. All patients had had coronavirus infection 2-2.5 months before hospitalization. Main group included 29 patients, whom peroral
anticoagulant had been carried out in the next scheme: Rivaroxaban 40 mg qDay l st week, then Rivaroxaban 30 mg q Day for 2 weeks and Rivaroxaban 20 mg qDay for 3 months. Control group had taken standard scheme of therapy.
